Skip to main content
. 2020 Aug 17;38(28):3294–3303. doi: 10.1200/JCO.20.00522

FIG 2.

FIG 2.

The best percentage change in target lesions in patients with gastrointestinal stromal tumors receiving ripretinib 150 mg once daily as (A) second-line therapy, (B) third-line therapy, or (C) fourth-line or greater therapy. The waterfall plot shows the best percentage change in target lesions regardless of confirmation of response.